Immunic, Inc. (IMUX) NASDAQ
1.26
-0.06(-4.55%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
1.26
-0.06(-4.55%)
Currency In USD
Address
1200 Avenue of the Americas
New York City, NY 10036
United States of America (the)
Phone
332 255 9818
Sector
Healthcare
Industry
Biotechnology
Employees
91
First IPO Date
April 17, 2014
| Name | Title | Pay | Year Born |
| Daniel Vitt | Chief Executive Officer & Director | 777,749 | 1968 |
| Jason Tardio | Chief Operating Officer & President | 360,000 | 1978 |
| Duane D. Nash | Executive Chairman | 466,099 | 1971 |
| Glenn Whaley | Chief Financial Officer | 534,000 | 1968 |
| Andreas Muehler | Chief Medical Officer | 616,121 | 1964 |
| Hella Kohlhof | Chief Scientific Officer | 0 | 1974 |
| Inderpal Singh | General Counsel | 0 | 1967 |
| Patrick Walsh | Chief Business Officer | 0 | 1984 |
| Werner Gladdines | Chief Development Officer | 0 | 1979 |
| Jessica Breu | Head of Investor Relations & Communications | 0 | N/A |
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.